Singlet Oxygen Detector for Photodynamic Therapy

用于光动力治疗的单线态氧检测器

• 批准号: 6690667
• 负责人: STEVEN J DAVIS
• 金额: $ 39.28万
• 依托单位: PHYSICAL SCIENCES, INC
• 依托单位国家: 美国
• 财政年份: 2002
• 资助国家: 美国
• 起止时间: 2002-05-01 至 2005-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6690667
• 关键词: biomedical equipment development; clinical research; human subject; laboratory rat; method development; neoplasm /cancer photoradiation therapy; neoplastic cell; oximetry; patient monitoring device; photomultiplier; photosensitizing agents; porphyrins; singlet oxygen

DESCRIPTION (provided by applicant): Photodynamic therapy (PDT) is a promising cancer treatment. PDT uses the affinity of photosensitizers such as hematoporphyrin derivative (HPD) and other compounds to be selectively retained in malignant tumors. When tumors, pretreated with the photosensitizer, are irradiated with visible light, a photochemical reaction occurs and tumor cells are destroyed. Oxygen molecules in their metastable singlet delta state O2 (1delta) are believed to be the species that destroys cancerous cells during PDT. A real-time optical diagnostic for singiet oxygen in-vivo would be a valuable dosimeter during PDT treatment. Based on a successful Phase I program, Physical Sciences Inc. proposes to develop and test a real-time optical monitor for singlet oxygen. We will use diode laser technology and ultra-sensitive photon counting methods. Extensive in-vitro testing will be performed using several photosensitizers. Crucial in-vivo tests will also be performed on tumor models in laboratory rats. These tests will be performed with our collaborators at the Massachusetts General Hospital. Success will lead to a product for medical research in PDT. The successful demonstration of the diagnostic could lead to numerous applications. For example, one could study the photo-induced HPD process in much more detail. New porphyrin compounds could be screened for O2 (1delta) production efficiency. Finally a real time O2 (1delta) monitor during phototherapy could be an invaluable tool for improving the efficiency of cancer cell destruction.

描述（由申请人提供）：光动力疗法（PDT）是一种有前途的癌症治疗方法。 PDT利用血卟啉衍生物（HPD）等光敏剂等化合物的亲和力选择性地保留在恶性肿瘤中。 当用光敏剂预处理的肿瘤受到可见光照射时，会发生光化学反应并破坏肿瘤细胞。处于亚稳态单线 δ 态 O2 (1delta) 的氧分子被认为是在 PDT 过程中破坏癌细胞的物质。体内单氧的实时光学诊断将是 PDT 治疗期间有价值的剂量计。基于成功的第一阶段计划，Physical Sciences Inc. 提议开发和测试单线态氧的实时光学监测仪。我们将使用二极管激光技术和超灵敏光子计数方法。将使用几种光敏剂进行广泛的体外测试。还将在实验室大鼠的肿瘤模型上进行重要的体内测试。这些测试将与我们在马萨诸塞州总医院的合作者一起进行。 成功将带来用于 PDT 医学研究的产品。诊断的成功演示可能会带来大量应用。例如，人们可以更详细地研究光诱导 HPD 过程。可以筛选新的卟啉化合物以提高 O2 (1delta) 的生产效率。最后，光疗期间的实时 O2 (1delta) 监测器可能是提高癌细胞破坏效率的宝贵工具。